FDA isn't recommending label change for ADHD drugs

04/10/2011 | Reuters

The FDA is not requiring drugmakers to change usage and safety information for Shire's Adderall XR, Novartis' Ritalin and other stimulants for attention-deficit/hyperactivity disorder. The agency said it will provide an update after it finishes analyzing ADHD drugs' potential risk of cardiovascular events.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC